The scientists have provided new insights into how mutations in a gene called TBK1 cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that robs patients of movement, speech and ultimately, their lives. The researchers found that ALS-associated mutations in TBK1 can have both positive and negative effects on the progression of disease in mice genetically modified to have ALS-like symptoms.
These findings, reported in Neuron, provide both genetic and mechanistic insights that could lead to novel strategies for the development of treatments for ALS.
"One of the greatest challenges to finding a cure for ALS is using genetic data to understand the disease's underlying mechanisms," said the study's senior author. "For example, neurodegenerative diseases such as ALS involve multiple cell types that are constantly changing as the disease progresses, so a drug that is beneficial in the early stages of the disease could detrimental at later times. Our study provides a glimpse into the complex relationship between ALS genetics and its mechanisms, and highlights the challenge in developing safe and effective drugs to treat the disease," commented the author.
ALS is a disease of the spinal cord, which can be triggered by the accumulation of misfolded proteins in motor neurons, the nerve cells in the spinal cord that drive movement.
The human TBK1 gene is one of more than 25 genes that have been shown associate with or cause ALS when bearing a mutation. TBK1 is a central player in multiple cellular functions, including autophagy, a process that removes misfolded proteins, damaged bits of cells and bacterial pathogens. TBK1 is also required for the antimicrobial interferon response, which protects cells from bacterial and viral infections.
"TBK1 helps cells clear away clumps of misfolded proteins and defends the body against invading viruses and bacteria," said the paper's lead author. "And because individuals with certain mutations in TBK1 have ALS, we wanted to develop a deep, mechanistic understanding of how these mutations affect cellular functions in the spinal cord during the course of the disease."
The authors inserted ALS-causing TBK1 mutations in mice. These mice showed no signs of motor neuron disease.
"This was not surprising, as only a few of the many human ALS mutations tested thus far in mice by other ALS researchers have resulted in motor neuron disease," said the senior author.
In an attempt to overcome this problem, the researchers inserted TBK1 mutations into an already established mouse model of ALS: the SOD1 mouse and then tracked disease progression in these mice.
These new mice displayed striking differences in disease progression compared to mice that only bear the SOD1 mutations. Specifically, the disease onset began earlier.
"We found that mice bearing both SOD1 and TBK1 mutations experienced earlier movement abnormalities compared to those bearing only SOD1 mutations," said the lead. "A closer examination of the mice also revealed damage to motor neurons and the loss of muscle connections earlier than expected."
To further investigate this phenomenon, the scientists examined another group of SOD1 ALS mice, in which the TBK1 gene was deleted only in motor neurons, and not in other cells in the spinal cord. The team found that the absence of TBK1 activity in motor neurons alone led to the loss of autophagy in these cells. This loss led to an increase in the accumulation of harmful proteins, earlier death of motor neurons, and lost neuron-muscle connections. These observations demonstrated that early disease onset was a consequence of losing TBK1 in motor neurons.
Paradoxically, however, disease progression slowed down later in disease, and mice with TBK1 loss of function in all cells lived 25 percent longer than both the mice bearing only SOD1, as well as those mice for which the TBK1 gene was deleted only in motor neurons.
The team next investigated precisely how TBK1 mutations influenced other cells in the spinal cord. The researchers discovered that the interferon response was suppressed in glial cells, namely astrocytes and microglia. The interferon response, while critical for defense against infections in healthy people, can be toxic if over produced (as in the case of ALS mice), and can trigger a cascade of cellular processes that are toxic to motor neurons.
"The loss of TBK1 in microglia and astrocytes clearly diminishes the interferon response in the spinal cord of ALS mice," said the senior author. "This correlates with significantly extending their lives."
"Our study provides an example of how multiple pathways within and between cells can be targeted through manipulation of a single gene, and how modifying these pathways in ALS can be beneficial -- or detrimental -- at different stages of disease progression," the lead added.
The senior author argues that this type of foundational, discovery-driven research will move the needle toward treatments that focus on the underlying mechanisms driving ALS and its devastating symptoms.
"All neurodegenerative diseases ultimately begin with genes," said the senior author. "As we continue to gather critical genetic information, we can identify mutations, like those in TBK1, which will provide additional mechanistic insights. These genes and the pathways they control will hold the key to developing drugs that make a difference in the life of ALS patients."
https://zuckermaninstitute.columbia.edu/double-edged-sword-scientists-identify-gene-initially-slows-then-later-accelerates-disease
https://www.cell.com/neuron/fulltext/S0896-6273(20)30191-4
A gene mutation either slows or accelerates ALS
- 2,209 views
- Added
Edited
Latest News
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Mapping microbiome in metas…
By newseditor
Posted 22 Apr
Full-length mRNA packaged i…
By newseditor
Posted 22 Apr
Glucose-sensing mechanism t…
By newseditor
Posted 21 Apr
Other Top Stories
How a non-coding RNA encourages cancer growth and metastasis
Read more
Nanoparticles to detect and kill circulating tumor cells (CTCs)
Read more
Quantum dot imaging system to detect cancer!
Read more
FDA Approves Personalized Cellular Therapy for Advanced Leukemia
Read more
Prostate cancer recurrence linked to DNA repair enzyme!
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Neuronal activity rapidly r…
By newseditor
Posted 22 Apr
A perspective on muscle phe…
By newseditor
Posted 22 Apr
Foxp1 suppresses cortical a…
By newseditor
Posted 22 Apr
Single-cell long-read seque…
By newseditor
Posted 22 Apr
Unlocking potential: the ro…
By newseditor
Posted 22 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar